Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

48.30 +0.40 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,220,649
Open 47.76
Bid (Size) 48.30 (100)
Ask (Size) 49.00 (1,000)
Prev. Close 47.90
Today's Range 47.44 - 48.60
52wk Range 30.04 - 49.06
Shares Outstanding 388,132,400
Dividend Yield 1.95%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Value Stock for Long-Term Investors and 2 Facing Challenges
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory

Performance

YTD
+24.3%
+24.3%
1 Month
+5.4%
+5.4%
3 Month
+16.7%
+16.7%
6 Month
+34.1%
+34.1%
1 Year
+56.6%
+56.6%

More News

Read More
News headline image
1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm
Via StockStory
Topics Energy
News headline image
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment ↗
Via Chartmill
ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗
Via Chartmill
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat ↗
Via Chartmill
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
Via Finterra
Topics Economy Initial Public Offering
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?
Via StockStory
Topics Artificial Intelligence Stocks Supply Chain
News headline image
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Expansion of Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 Healthcare Stocks Walking a Fine Line
Via StockStory
Topics Stocks
News headline image
5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call
Via StockStory
Topics Earnings
News headline image
Patient Capital Bet Heavily on Chime Financial (CHYM) With a 2.04 Million Share Purchase ↗
Via The Motley Fool
News headline image
Royalty Pharma (RPRX) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
Topics Bonds
News headline image
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings
Via StockStory
News headline image
Royalty Pharma Reports Q4 and Full Year 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings
Via StockStory
Topics World Trade
News headline image
3 Mid-Cap Stocks We Keep Off Our Radar
Via StockStory
News headline image
3 Profitable Stocks with Open Questions
Via StockStory
News headline image
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
From Royalty Pharma plc
Via GlobeNewswire

Frequently Asked Questions

Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 48.30
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 04/09/26 04:00 PM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 18.75B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 19B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.